These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 16372298

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays.
    Ogawa E, Furusyo N, Murata M, Toyoda K, Eiraku K, Shimizu M, Harada Y, Mitsumoto F, Takayama K, Okada K, Kainuma M, Hayashi J.
    Antiviral Res; 2013 Aug; 99(2):119-24. PubMed ID: 23684903
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
    Kawai S, Yokosuka O, Imazeki F, Saisho H, Mizuno C.
    J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P, Italian Co-infection Study (ICOS) Group.
    Antivir Ther; 2005 Nov; 10(2):309-17. PubMed ID: 15865225
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF, Fernández-Carbia A, González-Lassalle E, Salgado-Mercado R, Marxuach-Cuétara AM.
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [Abstract] [Full Text] [Related]

  • 31. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.
    Vermehren J, Aghemo A, Falconer K, Susser S, Lunghi G, Zeuzem S, Colombo M, Weiland O, Sarrazin C.
    J Hepatol; 2014 May; 60(5):913-9. PubMed ID: 24424305
    [Abstract] [Full Text] [Related]

  • 32. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V, Núñez M, Camino N, Maida I, Barreiro P, Romero M, Martin-Carbonero L, Garcia-Samaniego J, González-Lahoz J.
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay.
    Ferraro D, Giglio M, Bonura C, Di Marco V, Mondelli MU, Craxì A, Di Stefano R.
    J Viral Hepat; 2008 Jan; 15(1):66-70. PubMed ID: 18088247
    [Abstract] [Full Text] [Related]

  • 36. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
    Veillon P, Payan C, Picchio G, Maniez-Montreuil M, Guntz P, Lunel F.
    J Clin Microbiol; 2003 Jul; 41(7):3212-20. PubMed ID: 12843066
    [Abstract] [Full Text] [Related]

  • 37. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C, ANRS HCO2 RIBAVIC Study Team.
    JAMA; 2004 Dec 15; 292(23):2839-48. PubMed ID: 15598915
    [Abstract] [Full Text] [Related]

  • 38. The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1.
    Bárcena R, Moreno A, del Campo S, Muriel A, Mateos ML, Garrido E, García M, Quereda C, Moreno S, Moreno A.
    Antivir Ther; 2007 Dec 15; 12(3):401-6. PubMed ID: 17591030
    [Abstract] [Full Text] [Related]

  • 39. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK.
    J Viral Hepat; 2007 Oct 15; 14(10):721-9. PubMed ID: 17875007
    [Abstract] [Full Text] [Related]

  • 40. [Comparison of hepatitis C viral RNA and core antigen kinetics in the therapeutic follow up of hepatitis C virus and human immunodeficiency virus co-infected patients, treated by bitherapy interferon-ribavirin, within the framework of RIBAVIC protocol].
    Pivert A, Payan C, Lunel F, Conseil Scientifique de RIBAVIC.
    Pathol Biol (Paris); 2004 Nov 15; 52(9):522-8. PubMed ID: 15531116
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.